Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.daiichisankyo.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
512 articles about Daiichi Sankyo
-
Daiichi Sankyo Co Ltd. Selects IntraLinks, Inc. for Secure Information Sharing
1/19/2010
-
IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to WELCHOL(R) 625 mg Tablets
1/15/2010
-
Rigel Pharmaceuticals, Inc. Receives Milestone Payment from Daiichi Sankyo Co Ltd. for Cancer Ligase Target
12/23/2009
-
KineMed, Inc. Receives an Investigator-Initiated Study Grant From Daiichi Sankyo Co Ltd. to Further Explore Mechanism(s) of Action Associated with Welchol(R) (colesevelam HCl) in Type 2 Diabetes Mellitus
11/20/2009
-
BioInvent Signs Licensing Agreement with Daiichi Sankyo Co Ltd. for the Discovery and Development of Therapeutic Antibodies
11/13/2009
-
MorphoSys AG and Daiichi Sankyo Co Ltd. Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
10/20/2009
-
Daiichi Sankyo Co Ltd.'s Welchol(R) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia Welchol for Oral Suspension Also Approved by FDA
10/7/2009
-
Hovione: Daiichi Sankyo Co Ltd.'s Influenza Drug Successful in Trials
9/9/2009
-
UK Body Backs Limited Use of Eli Lilly and Company (JOBS), Daiichi Sankyo Co Ltd. Anti-Clot Drug
9/4/2009
-
Daiichi Sankyo Co Ltd. Inks Five-Year Agreement with Synygy for Sales Performance Management Solutions
8/28/2009
-
Daiichi Sankyo Co Ltd. Release: Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
7/15/2009
-
Daiichi Sankyo Co Ltd. Seeks Biotechnology, Cardiovascular Takeovers
6/10/2009
-
Daiichi Sankyo Co Ltd. Release: The Pressure Is on for African Americans With Hypertension
6/10/2009
-
Letter Urging the FDA to Halt its Review of Eli Lilly and Company (JOBS) and Daiichi Sankyo Co Ltd. Prasugrel
6/4/2009
-
American Society of Clinical Oncology Presentations Highlight Findings from Clinical Trials with ArQule, Inc. And Daiichi Sankyo Co Ltd.'s c-MET Inhibitor, ARQ 197
6/1/2009
-
Daiichi Sankyo Co Ltd. and Ranbaxy Laboratories Announces CEO, Mr. Malvinder Mohan Singh Steps Down
5/26/2009
-
Daiichi Sankyo Co Ltd. and MorphoSys AG Expand Collaboration With Two New Cancer-Related Antibody Programs
5/18/2009
-
Daiichi Sankyo Co Ltd.: Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
5/15/2009
-
Daiichi Sankyo Co Ltd.'s AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
5/13/2009
-
Daiichi Sankyo Co Ltd. Celebrates the Growth of Its U.S. Headquarters
5/13/2009